BioNTech SE (BNTX) Operating Income (2018 - 2025)
BioNTech SE (BNTX) posted Operating Income of -$375.8 million for Q4 2025, down 585.32% sequentially from -$54.8 million in Q3 2025, and down 336.63% YoY from $158.8 million in Q4 2024.
BioNTech SE (BNTX) Operating Income (2018 - 2025) Analysis & Trends
BioNTech SE has reported Operating Income for 8 years, with the latest figure at -$375.8 million in Q4 2025.
- Quarterly Operating Income fell 336.63% year-over-year to -$375.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 billion (down 9.74% YoY) and the FY2025 annual result came in at -$1.6 billion, down 13.02% from the prior year.
- Operating Income declined to -$375.8 million in Q4 2025 per BNTX's latest filing, from -$54.8 million in the prior quarter.
- Over five years, Operating Income peaked at $6.1 billion in Q1 2022 and troughed at -$1.0 billion in Q2 2024.
- A 5-year average of $1.4 billion and a median of $119.2 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income jumped 62488226.12% in 2022, then tumbled 575.48% in 2025.
- Over 5 years, Operating Income stood at $5376.3 in 2021, then surged by 62488226.12% to $3.4 billion in 2022, then tumbled by 83.15% to $566.2 million in 2023, then slumped by 71.95% to $158.8 million in 2024, then tumbled by 336.63% to -$375.8 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$375.8 million, -$54.8 million, and -$567.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Roivant Sciences | 26.52 Bn | 26.52 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -375.75 Mn |
| Sep 30, 2025 | -54.83 Mn |
| Jun 30, 2025 | -567.22 Mn |
| Mar 31, 2025 | -561.81 Mn |
| Dec 31, 2024 | 158.79 Mn |
| Sep 30, 2024 | 11.53 Mn |
| Jun 30, 2024 | -1.04 Bn |
| Mar 31, 2024 | -551.00 Mn |
| Dec 31, 2023 | 566.16 Mn |
| Sep 30, 2023 | 79.58 Mn |
| Jun 30, 2023 | -613.39 Mn |
| Mar 31, 2023 | 702.39 Mn |
| Dec 31, 2022 | 3.36 Bn |
| Sep 30, 2022 | 3.22 Bn |
| Jun 30, 2022 | 5.07 Bn |
| Mar 31, 2022 | 6.12 Bn |
| Dec 31, 2021 | 5.38 Bn |
| Sep 30, 2021 | 5.57 Bn |
| Jun 30, 2021 | 5.06 Bn |
| Mar 31, 2021 | 2.01 Bn |